GlassScriptPhysician profile
Richard Scott Groat
NPI 1497011274
$4,037.63
in general payments reported to CMS, 2019-2025
24 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $499 · 2021: $637 · 2022: $713 · 2023: $822 · 2024: $341 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $671.66 | 2019-2025 | Argos, Clareon, Rocklatan |
| Abbvie INC. | $464.40 | 2022-2025 | |
| Allergan, INC. | $392.41 | 2019-2021 | |
| Oyster Point Pharma, INC. | $359.52 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $327.20 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $312.62 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Novartis Pharmaceuticals Corporation | $245.46 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $236.93 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $160.42 | 2020-2022 | |
| Horizon Therapeutics Plc | $141.70 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $140.15 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $138.62 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $113.22 | 2020 | |
| Sun Pharmaceutical Industries INC. | $85.76 | 2019-2022 | |
| Amgen INC. | $56.39 | 2025 | Tepezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $35.07 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $31.00 | 2022-2023 | Visumax |
| Biotissue Holdings INC. | $22.51 | 2025 | |
| Thea Pharma INC. | $22.37 | 2023 | Iyuzeh |
| Sight Sciences, INC. | $21.51 | 2024 | Omni Surgical System |
| Glaukos Corporation | $19.66 | 2025 | Idosetr |
| Harrow Eye, LLC | $13.96 | 2025 | |
| Omeros Corporation | $12.55 | 2019 | |
| Eyepoint US, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Groat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.